Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus
暂无分享,去创建一个
[1] R. Semelka,et al. Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo? , 2016, Investigative radiology.
[2] D. Reich,et al. National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain. , 2016, Journal of the American College of Radiology : JACR.
[3] K. Maravilla,et al. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function , 2016, Investigative radiology.
[4] S. Lehéricy,et al. Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats , 2016, Investigative radiology.
[5] M. Prince,et al. Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol. , 2016, AJR. American journal of roentgenology.
[6] H. Thomsen. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium – 1997–2006–2016. Part 1 , 2016, Acta radiologica.
[7] H. Thomsen. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium – 1997–2006–2016. Part 2 , 2016, Acta radiologica.
[8] H. Thomsen. T1 hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents , 2016, Acta radiologica.
[9] H. Thoeny,et al. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1‐weighted MR images in three patients with impaired renal function and vascular calcification , 2016, Contrast media & molecular imaging.
[10] D. Stojanov,et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol , 2016, European Radiology.
[11] V. Runge. Macrocyclic Versus Linear Gadolinium Chelates. , 2015, Investigative radiology.
[12] Alexander Radbruch,et al. High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images: Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol , 2015, Investigative radiology.
[13] Pascal J. Kieslich,et al. Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration , 2015, Investigative radiology.
[14] W. Brooks,et al. Do ASARM peptides play a role in nephrogenic systemic fibrosis? , 2015, American journal of physiology. Renal physiology.
[15] M. Taupitz,et al. Contrast Media for X-ray and Magnetic Resonance Imaging: Development, Current Status and Future Perspectives , 2015, Investigative radiology.
[16] V. Runge. Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. , 2015, Investigative radiology.
[17] C. Mallio,et al. Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy. , 2015, Investigative radiology.
[18] Richard C. Semelka,et al. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. , 2015, Radiology.
[19] Pascal J. Kieslich,et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.
[20] David F Kallmes,et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.
[21] U. Karst,et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. , 2015, Analytical chemistry.
[22] John N Morelli,et al. T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3, and 7 T , 2015, Investigative radiology.
[23] Shigeru Furui,et al. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.
[24] C. Robic,et al. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update , 2014, Critical reviews in toxicology.
[25] M. Port,et al. Analytical Interference in Serum Iron Determination Reveals Iron Versus Gadolinium Transmetallation With Linear Gadolinium-Based Contrast Agents , 2014, Investigative radiology.
[26] Vincenzo Di Lazzaro,et al. Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.
[27] Daisuke Takenaka,et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.
[28] J. Gauvrit,et al. Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents: The Prospective Fibrose Nephrogénique Systémique Study , 2014, Investigative radiology.
[29] V. Runge,et al. MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.
[30] Joseph E. Mazurkiewicz,et al. Friedreich's Ataxia Causes Redistribution of Iron, Copper, and Zinc in the Dentate Nucleus , 2012, The Cerebellum.
[31] V. Runge,et al. The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance , 2011, Investigative radiology.
[32] M. Port,et al. Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.
[33] M. Lockhart,et al. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. , 2011, Radiology.
[34] V. Runge. Gadolinium and nephrogenic systemic fibrosis. , 2009, AJR. American journal of roentgenology.
[35] A. Rajput,et al. Iron, Copper, and Zinc Distribution of the Cerebellum , 2009, The Cerebellum.
[36] T. Frenzel,et al. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.
[37] J. L. Abraham,et al. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. , 2008, European journal of radiology.
[38] C. Robic,et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.
[39] H. Thomsen,et al. High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.
[40] T. Frenzel,et al. A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.
[41] H. Schmitt-Willich. Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.
[42] S. Morcos,et al. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.
[43] V. Runge,et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.
[44] Z. Chai,et al. Neurotoxicological consequence of long-term exposure to lanthanum. , 2006, Toxicology letters.
[45] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[46] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[47] T. Balzer,et al. Interference of Gadolinium-Containing Contrast-Enhancing Agents With Colorimetric Calcium Laboratory Testing , 2005, Investigative radiology.
[48] V. Runge,et al. Subchronic toxicity of the gadolinium chelates. , 2005, Academic radiology.
[49] K. Kent,et al. Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.
[50] M. Tweedle. Using Radiotracers to Characterize Magnetic Resonance Imaging Contrast Agents , 2002, Investigative radiology.
[51] V. Runge. Allergic reactions to gadolinium chelates. , 2001, AJR. American journal of roentgenology.
[52] M. Port,et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.
[53] V. Runge,et al. Worldwide clinical safety assessment of gadoteridol injection: an update , 1997, European Radiology.
[54] W. Gibby,et al. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. , 1996, Investigative radiology.
[55] W. Blazak,et al. Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats. , 1995, Teratology.
[56] P. Normann,et al. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.
[57] E. Holtz,et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.
[58] B. Drayer,et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. , 1991, Radiology.
[59] H. Niendorf,et al. Tolerance data of Gd-DTPA: a review. , 1991, European journal of radiology.
[60] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[61] J. Hagan,et al. Comparative Chemical Structure and Pharmacokinetics of MRI Contrast Agents , 1988, Investigative radiology.
[62] M. Schaefer,et al. Gd‐DOTA, A Potential MRI Contrast Agent Current Status of Physicochemical Knowledge , 1988, Investigative radiology.
[63] J. Hagan,et al. Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[64] P. Wedeking,et al. Comparison of the biodistribution of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[65] グレン・ティー・ゴーギャン,et al. 10- substituted 1,4,7-tris-carboxymethyl -1,4,7,10 tetraazacyclododecane and analogs , 1987 .
[66] R. G. Stewart,et al. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. , 1983, Radiology.